Clinical Trial

IMarkHD: in Vivo Longitudinal Imaging of HD Pathology

Recruiting
View on ClinicalTrials.gov →
Summary
iMarkHD is an adaptive, longitudinal positron emission tomography (PET) and magnetic resonance (MR) imaging study in Huntington's disease (HD) that aims to assess abnormal molecular, functional, and structural changes in participants' brains, ranging from several years before symptom onset to the advanced symptom stage. The study will be conducted over a three (3) year period (Baseline, Year-1, and Year-2).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2018-02-13; most recent amendment 2025-03-03.
Status change: Not Yet Recruiting → Recruiting 2022-10-12
Trial Details
NCT Number NCT03434548
Lead Sponsor King's College London
Collaborators: CHDI Foundation, Inc.
Conditions Huntington Disease
Enrollment 113 participants
Start Date 2021-07-20
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-05